Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11233691 | 1.00 | KDM4E (0.31) | KDM4ETSHRHSD17B10TDP1 | |
| SCHEMBL14381086 | 1.00 | KDM4E (0.31) | KDM4ETSHRHSD17B10TDP1 | |
| SCHEMBL11962161 | 0.81 | — | — | |
| SCHEMBL9069749 | 0.81 | — | — | |
| SCHEMBL7127888 | 0.81 | — | — | |
| SCHEMBL25263944 | 0.80 | KCNH2 (0.34) | — | |
| SCHEMBL9771533 | 0.80 | KCNH2 (0.30) | — | |
| SCHEMBL24961316 | 0.79 | — | — | |
| SCHEMBL23802856 | 0.79 | KDM4E (0.35) | KDM4ETSHRHSD17B10 | |
| SCHEMBL23802915 | 0.79 | KDM4E (0.35) | KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2020-07-09 | — | — | US | disclosed |
| EP-1400521-B1 | PIPERAZINE COMPOUNDS | KOWA CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| CN-1309720-C | Piperazine compounds | KOWA CO (JP) | 2007-04-11 | — | — | CN | disclosed |
| CN-1520408-A | Piperazine compounds | ������������ʽ���� | 2004-08-11 | — | — | CN | disclosed |
| EP-1400521-A1 | PIPERAZINE COMPOUNDS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6432957-B1 | ANTIASTHMA; ANTIALLERGENS; RHEUMATIC DISEASES; ANTIINFLAMMATORY AGENTS | KOWA CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | KDM4E 1634/4885TSHR 4245/4885HSD17B10 3104/4885 |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | KDM4E 2707/4885TSHR 1397/4885HSD17B10 3023/4885 |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | KDM4E 1634/4885TSHR 4245/4885HSD17B10 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.